



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Promise of immuno-oncology therapies is boosting R&D funding, alliances

mAbs, vaccines, T cell engineering lead I/O product development

- Range of tumors studied in clinical trials during 2013-15 spanned 28 cancers.
- More than 130 biotech and 20 pharma companies worldwide are working on I/O therapies.
- I/O is also driving major engagement between pharma and universities/cancer centers.
- Total I/O oncology alliance R&D funding commitments increased nearly tenfold from 2013 to 2015.
- Alliances between pharma/big biotech and small enterprises grew from 6 in 2013 to 58 in 2015.